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Background
Transthyretin Familial Amyloid Polyneuropathy (TTR-
FAP) is a rare, progressive, debilitating and life-threatening
neurodegenerative disease. The purpose of this study was
to assess the health-related quality of life (HRQoL) impair-
ment of TTR-FAP disease versus Portuguese general
population and to identify individual patient characteris-
tics - such as disease stage – that affects their HRQoL.
Literature on TTR-FAP patients HRQoL is scarce at
worldwide level and no evidence for Portugal has been
published.
Methods
HRQoL was measured using the validated EuroQoL five
dimensions three levels (EQ5D-3L) questionnaire being
the index score (utility) calculated trough the Portuguese
scoring algorithm. The Portuguese general population
reference set (n = 1500) was pooled with TTR-FAP
patients specific data extracted from Transthyretin
Amyloidosis Outcomes Survey (THAOS) registry. Ordin-
ary Least Squares regression for utility was set to test if
being asymptomatic carrier caused HRQoL impairment,
conditional in other individual characteristics. Generalized
linear models (GLM) were specified for disutility in order
to disentangle individual patient characteristics that affect
quality of life and quantify the impact. Demographic vari-
ables include gender and age. Clinical variables include
disease onset (early/late), polyneuropathy disability (PND)
score, liver transplant and pharmacologic treatment.
Akaike information criteria were used to select the most
adequate statistical model.
Results
In a scale from -0.50 to 1.00 the average utility score was
0.76 (0.25) for general population, 0.823 (0.24) for
TTR-FAP asymptomatic carriers (n=525) and 0.50 (0.37)
for symptomatic TTR-FAP patients (n = 566). Ordinary
Least Squares regression indicated no significant statistical
effect on utility for being a TTR-FAP asymptomatic carrier
versus general population (p-value 0.54). The GLM was
used to detect a significant statistical effect for gender, age
and being symptomatic TTR-FAP patient versus general
population. Average women aged 44 years and sympto-
matic TTR-FAP patient, has average 40% impairment on
utility versus women aged 44 years from general popula-
tion. Within TTR-FAP population, individual patient char-
acteristics such as gender, age, disease onset (early/late),
polyneuropathy disability (PND) score, liver transplant
and pharmacologic treatment were tested for significant
statistical effect (p-value <0.005).
Conclusion
The preference-based utility measures used in this study
adequately quantify the large impact of TTR-FAP disease
on patient’s health-related quality of life and allow discri-
minating across different TTR-FAP clinical stages, inter-
ventions and demographic characteristics. Assuming that
these values represent the patients’ preferences and the
utility associated with their health state, the results
presented in this study may be used in future health tech-
nologies cost-utility studies.
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